Kansas City, Kan- Dr. Sean Kumer and his panel discuss the advancements and challenges in CAR-T cell therapy for cancer treatment.

They highlight the success of CAR T-cell therapy in blood cancers, with patients achieving long-term remission, and the potential for solid tumor treatments.

The University of Kansas Cancer Center offers all seven FDA-approved CAR-T therapies, with an average cell collection time of 23 days, faster than the national average of 38 days.  

Dr. Sean Kumer, chief medical officer, Kansas City division; VP, Perioperative and Procedural Services, The University of Kansas Health System

• Dr. Kumer introduces Car T-cell therapy as a curative treatment for blood cancers, highlighting the need to increase awareness and access.

Dr. Joseph McGuirk, hematologist & medical oncologist; director of hematologic malignancies and cellular therapies, The University of Kansas Cancer Center

• Dr. McGuirk confirms that Car T-cell therapy has led to long-term remissions for patients with blood cancers.

Dr. Marc Hoffman, director, lymphoma program, The University of Kansas Cancer Center

• Dr. Hoffman emphasizes the importance of patient and public education to increase access to Car T-cell therapy.

Dr. Raed Al-Rajabi, Physician Researcher, GI medical oncology, The University of Kansas Cancer Center

• Dr. Al-Rajabi highlights the focus on identifying effective targets for Car T-cell therapy in solid tumors and the potential for new cellular therapeutics.

Dr. David Akhavan, translational physician scientist, radiation oncology, The University of Kansas Cancer Center

• Dr. Akhavan discusses research on using Car T-cell therapy for solid tumors, including the use of drug-eluting polymers to enhance cytokine potential.